A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Major Depressive Disorder
Interventions
DRUG

Placebo

Form= capsule, route= oral use. Administration once daily for 8 weeks.

DRUG

Escitalopram

Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.

DRUG

JNJ-18038683

Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.

Trial Locations (26)

Unknown

Little Rock

Beverly Hills

Glendale

San Diego

Bradenton

Maitland

Orlando

Atlanta

Eagle

Chicago

Prairie Village

Topeka

Baton Rouge

Shreveport

Nutley

Brooklyn

Cedarhurst

Fresh Meadows

Cincinnati

Oklahoma City

Portland

Norristown

Memphis

Austin

Irving

Richmond

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00566202 - A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression | Biotech Hunter | Biotech Hunter